文献速递哮喘

氟替卡松糠酸酯与丙酸酯在哮喘中的剂量效应与时效定量比较

Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis.
PubMed 文献 · Respirology · 2022-01-18

本研究通过系统综述与荟萃分析,纳入14篇安慰剂对照试验共6640例青少年和成人持续性哮喘患者,建立药效学模型比较氟替卡松糠酸酯(FF)与丙酸酯(FP)的疗效时效。两种药物均在2周内达到疗效平台,FF在200 μg/日未达平台,FP在1000 μg/日已达平台;次要结局两药相对安慰剂效应相似且无明显剂量效应关系。

要点

  • FF与FP均在2周内达到疗效平台,FF在最大评估剂量200 μg/日未达平台。
  • 第2周谷FEV1较基线变化:FF 200 μg/日为0.168 L(95%CI 0.064-0.199)。
  • FP在1000 μg/日达疗效平台,第2周谷FEV1变化0.133 L(95%CI 0.049-0.171)。

核心结论

  • 定量评估了FP、FF与安慰剂的时效和剂量效应特征,为哮喘指南提供定量信息。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和EMBASE的安慰剂对照试验,纳入14篇文章共6640例青少年和成人哮喘患者,建立药效学模型描述主要结局谷FEV1的时效。

主要发现

  • 两种药物疗效平台均可在2周内达到。
  • 第2周谷FEV1较基线变化(95%CI):FF 200 μg/日为0.168 L(0.064-0.199),FF 100 μg/日为0.127 L(0.048-0.163)。
  • 第2周谷FEV1较基线变化(95%CI):FP 1000 μg/日为0.133 L(0.049-0.171),FP 500 μg/日为0.127 L(0.043-0.163),FP 250 μg/日为0.117 L(0.039-0.150),FP 100 μg/日为0.093 L(0.032-0.129)。
  • FP在最大评估剂量1000 μg/日已达平台,FF在最大评估剂量200 μg/日未见平台效应。
  • 次要结局(哮喘症状、生活质量、急性加重)两药相对安慰剂的效应相似,无明显剂量效应关系。

关键数值与推荐

  • FF 200 μg/日第2周谷FEV1较基线变化0.168 L(95%CI 0.064-0.199)。
  • FP 1000 μg/日第2周谷FEV1较基线变化0.133 L(95%CI 0.049-0.171)。
  • FP在1000 μg/日达平台,FF在200 μg/日未达平台。

临床怎么用

  • 提示FF与FP的起效时效均在2周内,可为哮喘吸入激素剂量选择提供定量参考。
  • FF在200 μg/日未达平台而FP在1000 μg/日已达平台,剂量调整时需考虑两者剂量效应差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to quantitatively compare the efficacy of fluticasone furoate (FF) and fluticasone propionate (FP) in adolescents and adults with asthma. We searched the PubMed and EMBASE databases for placebo-controlled trials that met the inclusion criteria. Pharmacodynamic models were established to describe the time-course of the primary outcome (trough forced expiratory volume in the first second [FEV1 ]). Secondary outcomes (asthma symptoms, quality of life and exacerbations) were also compared via a meta-analysis. A total of 14 articles were included in the analysis, involving 6640 subjects. The efficacy plateau of the two drugs could be reached in 2 weeks. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FF at 200 and 100 μg/day were 0.168 L (0.064-0.199) and 0.127 L (0.048-0.163), respectively. The changes from the baseline in trough FEV1 (95% CI) at week 2 of FP at 1000, 500, 250 and 100 μg/day were 0.133 L (0.049-0.171), 0.127 L (0.043-0.163), 0.117 L (0.039-0.150) and 0.093 L (0.032-0.129), respectively. The efficacy of FP had reached a plateau at the maximum evaluated dose (1000 μg/day), while a plateau effect was not seen at the maximum evaluated dose of FF (200 μg/day). In terms of secondary outcomes, the relative effects of the two drugs relative to the placebo were similar and did not show obvious dose-effect relationships. In this study, the time-course and dose-effect characteristics of FP, FF and placebo were quantitatively evaluated, providing necessary quantitative information for asthma-related guidelines.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Zhong Y, Li L, Chen R, et al. Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis. Respirology. 2022. PMID: 35043513. doi:10.1111/resp.14203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。